Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Western Database of Lipid Variants (WDLV): a catalogue of genetic variants in monogenic dyslipidemias.
Fu J, Kwok S, Sinai L, Abdel-Razek O, Babula J, Chen D, Farago E, Fernandopulle N, Leith S, Loyzer M, Lu C, Malkani N, Morris N, Schmidt M, Stringer R, Whitehead H, Ban MR, Dubé JB, McIntyre A, Johansen CT, Cao H, Wang J, Hegele RA. Fu J, et al. Can J Cardiol. 2013 Aug;29(8):934-9. doi: 10.1016/j.cjca.2013.01.008. Epub 2013 Apr 24. Can J Cardiol. 2013. PMID: 23623477
Significant Valvular Dysfunction and Outcomes in Cardiogenic Shock: Insights From the Randomized DOREMI Trial.
Parlow S, Weng W, Di Santo P, Jung RG, Lepage-Ratte MF, Motazedian P, Prosperi-Porta G, Abdel-Razek O, Simard T, Chan V, Labinaz M, Froeschl M, Mathew R, Hibbert B; CAPITAL DOREMI Investigators. Parlow S, et al. Can J Cardiol. 2022 Aug;38(8):1211-1219. doi: 10.1016/j.cjca.2022.04.004. Epub 2022 Apr 14. Can J Cardiol. 2022. PMID: 35430192 Clinical Trial.
No sex-based difference in cardiogenic shock: A post-hoc analysis of the DOREMI trial.
Prosperi-Porta G, Motazedian P, Di Santo P, Jung RG, Parlow S, Abdel-Razek O, Simard T, Hutson J, Malhotra N, Fu A, Ramirez FD, Froeschl M, Mathew R, Hibbert B; CAPITAL DOREMI investigators. Prosperi-Porta G, et al. J Cardiol. 2022 Oct;80(4):358-364. doi: 10.1016/j.jjcc.2022.06.001. Epub 2022 Jun 17. J Cardiol. 2022. PMID: 35725945 Free article. Clinical Trial.
Arrhythmic Events and Mortality in Patients With Cardiogenic Shock on Inotropic Support: Results of the DOREMI Randomized Trial.
Jung RG, Di Santo P, Mathew R, Simard T, Parlow S, Weng W, Abdel-Razek O, Malhotra N, Cheung M, Hutson JH, Marbach JA, Motazedian P, Thibert MJ, Fernando SM, Nery PB, Nair GM, Russo JJ, Hibbert B, Ramirez FD. Jung RG, et al. Can J Cardiol. 2023 Apr;39(4):394-402. doi: 10.1016/j.cjca.2022.09.013. Epub 2022 Sep 20. Can J Cardiol. 2023. PMID: 36150583 Clinical Trial.
A National Strategy to Detect and Treat Heart Valve Diseases in Canada.
Forcillo J, Wood DA, Abdel-Razek O, Adreak N, Asgar A, Chedrawy E, Eckstein J, Legare JF, Natarajan MK, Pibarot P, Styra R, Tyrrell B, Wijeysundera H, Messika-Zeitoun D; Canadian Cardiovascular Society Working Group on Heart Valve Disease. Forcillo J, et al. Can J Cardiol. 2023 May;39(5):567-569. doi: 10.1016/j.cjca.2023.01.021. Epub 2023 Jan 27. Can J Cardiol. 2023. PMID: 36716859 No abstract available.
Evaluation of plasminogen activator inhibitor-1 as a biomarker of unplanned revascularization and major adverse cardiac events in coronary angiography and percutaneous coronary intervention.
Jung RG, Simard T, Di Santo P, Dhaliwal S, Sypkes C, Duchez AC, Moreland R, Taylor K, Parlow S, Visintini S, Labinaz A, Marbach J, Sarathy K, Bernick J, Joseph J, Boland P, Abdel-Razek O, Harnett DT, Ramirez FD, Hibbert B. Jung RG, et al. Thromb Res. 2020 Jul;191:125-133. doi: 10.1016/j.thromres.2020.04.025. Epub 2020 Apr 24. Thromb Res. 2020. PMID: 32447094
Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock.
Mathew R, Di Santo P, Jung RG, Marbach JA, Hutson J, Simard T, Ramirez FD, Harnett DT, Merdad A, Almufleh A, Weng W, Abdel-Razek O, Fernando SM, Kyeremanteng K, Bernick J, Wells GA, Chan V, Froeschl M, Labinaz M, Le May MR, Russo JJ, Hibbert B. Mathew R, et al. N Engl J Med. 2021 Aug 5;385(6):516-525. doi: 10.1056/NEJMoa2026845. N Engl J Med. 2021. PMID: 34347952 Clinical Trial.
Impact of baseline beta-blocker use on inotrope response and clinical outcomes in cardiogenic shock: a subgroup analysis of the DOREMI trial.
Di Santo P, Mathew R, Jung RG, Simard T, Skanes S, Mao B, Ramirez FD, Marbach JA, Abdel-Razek O, Motazedian P, Parlow S, Boczar KE, D'Egidio G, Hawken S, Bernick J, Wells GA, Dick A, So DY, Glover C, Russo JJ, McGuinty C, Hibbert B; CAPITAL DOREMI investigators. Di Santo P, et al. Crit Care. 2021 Aug 10;25(1):289. doi: 10.1186/s13054-021-03706-2. Crit Care. 2021. PMID: 34376218 Free PMC article. Clinical Trial.
54 results